Liraglutide Added to Insulin Pumps Cuts Blood Sugar, Weight, and Insulin Needs in Type 1 Diabetes

Adding liraglutide 1.8 mg daily to insulin pump therapy in overweight adults with type 1 diabetes produced three significant benefits over 26 weeks compared to placebo: HbA1c dropped by 0.5% (vs. a 0.2% increase with placebo, p<0.001), body weight decreased by 6.3 kg (p<0.001), and total insulin dose fell by 8 units/day (16% reduction, p=0.008). Time in the target glucose range (71-180 mg/dL) increased without raising the risk of hypoglycemia.

26-week randomized, double-blind, placebo-controlled trial (Lira Pump trial). 44 overweight/obese adults with type 1 diabetes on insulin pump therapy (CSII) were randomized 1:1 to liraglutide 1.8 mg once daily or placebo. Primary endpoint was HbA1c change. Secondary endpoints included insulin dose, glycemic variability, body weight, and adverse events.

GLP-1 drugs are primarily used for type 2 diabetes and obesity, but some type 1 diabetes patients — especially those who are overweight with poor glucose control — may also benefit. This trial provides rigorous evidence that liraglutide can improve multiple outcomes simultaneously in these patients without the feared increase in dangerous low blood sugar episodes.

While GLP-1 drugs have transformed type 2 diabetes treatment, their role in type 1 diabetes remains off-label and debated. This well-designed trial adds to growing evidence that a subset of type 1 patients — particularly those who are overweight with insulin resistance features — can meaningfully benefit from GLP-1 therapy as an add-on to insulin, not a replacement for it.

Small sample size (44 patients total, 22 per group). Single-center trial. 26-week duration doesn't capture long-term outcomes or sustainability. Only studied the 1.8 mg dose. Results apply specifically to overweight/obese type 1 patients on insulin pumps — may not generalize to all type 1 diabetes patients. Liraglutide is not FDA-approved for type 1 diabetes.